Attention Deficit Hyperactive Disorder (ADHD) is a chronic disorder that affects over 128 million children and often continues into adulthood. It includes a combination of persistent problems: difficulty in sustaining attention, hyperactivity and impulsivity as well as behavioral issues. Proper diagnosis and ongoing monitoring can make an enormous difference in the patient’s quality of life. Current monitoring processes are mostly based on subjective, manual questionnaires, provided by educators and parents. This leads to an inefficient “trial and error” approach, resulting in poor treatment monitoring and enormous costs.
An Israeli company, Iluria, founded in 2018 developed a remote patient monitoring solution for ADHD. Iluria’s initial solution is a continuous, non-invasive, remote patient monitoring platform for ADHD, based on machine learning analysis of changes in physiological markers. Their platform analyzes changes physiological markers (through any smart wearable) by utilizing proprietary machine learning-based methods, to deliver personalized, objective & continuous monitoring. These monitoring processes are mostly trial-and-errors based, providing subjective and sporadic evaluations. The analysis of samples can be fully embedded in existing clinical workflows, either by replacing or enhancing current subjective methods.
The Economic Mission has been approached by the Israeli companies to get in touch with Relevant stakeholders in India. Iluria has shown interests in meeting Hospitals having Pediatrics department, Pharmaceutical and Insurance companies in India
For more information please contact: Tejinder Singh (Tejinder.Singh@israeltrade.gov.il)
Leave A Comment